A carregar...
Risk factors for the discontinuation of roflumilast in patients with chronic obstructive pulmonary disease
INTRODUCTION: Roflumilast is a phosphodiesterase-4 inhibitor, which can decrease exacerbation in patients with chronic obstructive pulmonary disease (COPD). However, adverse effects are a major barrier to medication use, and little is known regarding the risk factors for discontinuation of roflumila...
Na minha lista:
| Publicado no: | Int J Chron Obstruct Pulmon Dis |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5720347/ https://ncbi.nlm.nih.gov/pubmed/29270006 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S143967 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|